12:25 PM EDT, 03/31/2020 (MT Newswires) -- Teva Pharmaceutical (TEVA) was up almost 9.5% Tuesday as the US Patent and Trademark Office's Patent Trial and Appeal Board upheld three of the company's patents over a migraine treatment and rejected Eli Lilly's (LLY) claim that the patents are invalid, Bloomberg News reported Tuesday.
Lilly alleged that calcitonin gene-related peptide which is linked to migraines, was targeted for treating the condition before Teva filed its patent applications, Bloomberg reported.
Market Data 
Markets 
AI
